<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03461289</url>
  </required_header>
  <id_info>
    <org_study_id>AVXS-101-CL-302</org_study_id>
    <nct_id>NCT03461289</nct_id>
  </id_info>
  <brief_title>Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1</brief_title>
  <acronym>STRIVE-EU</acronym>
  <official_title>European, Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AveXis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AveXis, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 3, open-label, single-arm, single-dose, trial of AVXS-101 (gene replacement therapy) in
      patients with spinal muscular atrophy (SMA) Type 1 who meet enrollment criteria and are
      genetically defined by a biallelic pathogenic mutation of the survival motor neuron 1 gene
      (SMN1) with one or two copies of survival motor neuron 2 gene (SMN2). Up to 30 patients &lt; 6
      months (&lt; 180 days) of age at the time of gene replacement therapy (Day 1) will be enrolled.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 3, open-label, single-arm, single-dose, trial of AVXS-101 (gene replacement therapy) in
      patients with spinal muscular atrophy (SMA) Type 1 who meet enrollment criteria and are
      genetically defined by a biallelic pathogenic mutation of the survival motor neuron 1 gene
      (SMN1) with one or two copies of survival motor neuron 2 gene (SMN2). Up to 30 patients &lt; 6
      months (&lt; 180 days) of age at the time of gene replacement therapy (Day 1) will be enrolled.

      The trial includes a screening period, a gene replacement therapy period, and a follow-up
      period. During the screening period (Days -30 to -2), patients whose parent(s)/legal
      guardian(s) provide informed consent will complete screening procedures to determine
      eligibility for trial enrollment. Patients who meet the entry criteria will enter the
      in-patient gene replacement therapy period (Day -1 to Day 3). On Day -1, patients will be
      admitted to the hospital for pre-treatment baseline procedures. On Day 1, patients will
      receive a one-time intravenous (IV) infusion of AVXS-101, and will undergo in-patient safety
      monitoring over the next 48 hours. Patients may be discharged 48 hours after the infusion,
      based on Investigator judgment. During the outpatient follow-up period (Days 4 to End of
      Trial at 18 months of age), patients will return at regularly scheduled intervals for
      efficacy and safety assessments until the End of Trial when the patient reaches 18 months of
      age. After the End of Trial visit, eligible patients will be asked to rollover into the
      long-term follow up trial.

      All post-treatment visits will be relative to the date on which gene replacement therapy is
      administered, except for the 14 and 18 months of age visits, which will be relative to the
      patient's date of birth.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label, single-arm, single-dose, trial of AVXS-101</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sitting without support</measure>
    <time_frame>Through 18 months of age</time_frame>
    <description>Proportion of patients achieving the developmental milestone of sitting without support up to 18 months of age</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Through 14 months of age</time_frame>
    <description>Proportion of patients survivingl at 14 months of age</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>SMA</condition>
  <arm_group>
    <arm_group_label>AVXS-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AVXS-101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AVXS-101</intervention_name>
    <description>AVXS-101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) containing the human survival motor neuron (SMN) gene under the control of the cytomegalovirus (CMV) enhancer/chicken β-actin-hybrid promoter (CB).</description>
    <arm_group_label>AVXS-101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with SMA Type 1 as determined by diagnosis of SMA based on gene mutation
             analysis with biallelic SMN1 mutations (deletion or point mutations) and one or two
             copies of SMN2 [inclusive of the known SMN2 gene modifier mutation (c.859G&gt;C)]

          -  Patients must be &lt; 6 months (&lt; 180 days) of age at the time of AVXS-101 infusion

          -  Patients must have a swallowing evaluation test performed prior to administration of
             gene replacement therapy

        Exclusion Criteria:

          -  Previous, planned or expected scoliosis repair surgery/procedure prior to 18 months of
             age

          -  Use of invasive ventilatory support (tracheotomy with positive pressure) or pulse
             oximetry &lt; 95% saturation at screening

          -  Use or requirement of non-invasive ventilatory support for 12 or more hours daily in
             the two weeks prior to dosing

          -  Patient with signs of aspiration based on a swallowing test or whose weight-for-age
             falls below the 3rd percentile based on World Health Organization (WHO) Child Growth
             Standards [27] and unwilling to use an alternative method to oral feeding

          -  Participation in recent SMA treatment clinical trial (with the exception of
             observational cohort studies or non-interventional studies) or receipt of an
             investigational or commercial compound, product or therapy administered with the
             intent to treat SMA (eg, nusinersen, valproic acid,) at any time prior to screening
             for this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AveXis Medinfo</last_name>
    <role>Study Chair</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AveXis Medinfo</last_name>
    <phone>833-828-3947</phone>
    <email>medinfo@avexis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Ghent Neuromuscular reference center</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elke Devos</last_name>
      <email>elke.devos@uzgent.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neuropédiatrie - Centre de Référence des Maladies Neuromusculaires</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Catherine Defeldre</last_name>
      <email>Anne.Catherine.Defeldre@chrcitadelle.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Armand Trousseau</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arnaud Jollet</last_name>
      <email>a.jollet@institut-myologie.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre for Neuromuscular Disorders in children and adolescents University Clinic Essen, Childrens´ hospital</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Neuropädiatrie und Muskelerkrankungen</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sabine Wider</last_name>
      <email>sabine.wider@uniklinik-freiburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kinderklinik und Kinderpoliklinik der Ludwig Maximilian Universität</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christiane Eder</last_name>
      <email>Christiane.Eder@med.uni-muenchen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Gianninia Gaslini</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marina Pedemonte</last_name>
      <email>marinapedemonte@gaslini.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico &quot;G. Martino&quot;</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniela Quattrocchi</last_name>
      <email>daniela.quattrocchigl@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carlo Besta Neurological Research Institute</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angelina Campanella</last_name>
      <email>Angela.Campanella@istituto-besta.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Milan</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandra Govoni</last_name>
      <email>alessandra.govoni@policlinico.mi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Gemelli</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Rosaria Vizino</last_name>
      <email>mariarosaria.vizzino@guest.policlinicogemelli.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht Wilhelmina Kinderziekenhui</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fay-Lynn Asselman</last_name>
      <email>F.Asselman@umcutrecht.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Area Genetica Clínica y Molecular</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Scherezade Sarri</last_name>
      <email>scherezade.sarri@vhir.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gothenburg University Queen Silvia Children's Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna-Lena Tulinius</last_name>
      <email>anna-lena.tulinius@vgregion.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hinal Patel</last_name>
      <email>hinal.patel@ucl.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The John Walton Muscular Dystrophy Research Centre MRC Centre for Neuromuscular Diseases at Newcastle</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Peel</last_name>
      <email>Anna.peel1@newcastle.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://studysmanow.com</url>
    <description>patient recruitment website</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2018</study_first_submitted>
  <study_first_submitted_qc>March 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2018</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

